This article provides a thorough overview of the treatment of HER2-positive early-stage breast cancer to highlight knowledge gaps, illuminate the current state of the most effective treatment approaches, and provide insights into the promising findings of recent research that are more likely to shape future treatment strategies. This evidence concerns the gene ERBB2 and breast carcinoma.